FY2024 Financial Results Presentation
The interpretation audio uses the simultaneous interpretation from the meeting session. The interpretation audio will be re-recorded at a later date.

from the beginning

FY2024 Financial Results Presentation

Forward-Looking Statements

1. FY2024 Financial Results

Overview of FY2024 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

2. Business Update

Progress towards “Maximize 3ADCs”

Performance

Approved and Started Promotion

Co-development and Co-commercialization for MK-6070

Progress towards “Profit growth for current business and products”

Other Regional Initiatives

Progress towards “Identify and build pillars for further growth”

Acquisition of Intellectual Property Rights for Anti-TA-MUC1 Antibody

Progress towards “Create shared value with stakeholders”

FY2024 Annual Dividend Forecast

Flexible Acquisition of Own Shares (Results)

3. R&D Update

Progress towards “Maximize 3ADCs”

Achievements in FY2024: Pioneered New Classifications of HER2

Go Earlier in HER2 Positive Breast Cancer

Go Earlier in HER2 Positive Breast Cancer

Expand Earlier in HER2 Positive Gastric Cancer

1L Treatment for HER2 Overexpressing NSCLC

Expansion Beyond DESTINY-PanTumor02

New Challenge in Gynecological Cancers

Progress in FY2024: Breast Cancer

Progress in FY2024: NSCLC

Progress in EGFR mutated NSCLC

Enhance Neoadjuvant Treatment in Breast Cancer

Progress towards “Profit growth for current business and products”

Major Progress in FY2024

The Third Ph3 Study

Expanding Target Indication to mCRPC

Exploring Possibilities in Gastrointestinal Cancers

Progress in FY2024

ASCO 2025

ASCO Highlights 2025: IR conference call

News Flow

FY2025 News Flow

4. 5-Year Business Plan Update

Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)

5-Year Business Plan: Progress in FY2021-FY2024

5-Year Business Plan: Progress in FY2021-FY2024

Expectation on achieving FY2025 KPIs (as of Apr. 2025)

Oncology Revenue Forecast (as of Apr. 2025)

R&D Expense Forecast (as of Apr. 2025)

Forecast of FY2025 KPIs (as of Apr. 2025)

Daiichi Sankyo will contribute to the enrichment of quality of life around the world

5. FY2025 Forecast

FY2025 Forecast

FY2025 Annual Dividend Forecast

Flexible Acquisition of Own Shares (Resolution)

6. Appendix

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

5DXd ADCs Revenue (incl. Forex Impact)

5DXd ADCs Upfront and Milestone Payments

Well-balanced Investment for Growth and Shareholder Returns Cash Allocation

Major R&D Milestones (ENHERTU)

Major R&D Milestones (DATROWAY)

Major R&D Milestones (HER3-DXd, I-DXd, R-DXd)

Major R&D Milestones (Next Wave)

Major R&D Pipeline: 5DXd ADCs (1)

Major R&D Pipeline: 5DXd ADCs (2)

Major R&D Pipeline: Next Wave

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6